New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 17, 2013
15:32 EDTABBV, RHHBYAbbVie suspends Leukemia therapy trials. Bloomberg reports
AbbVie (ABBV) and its partner in the trials, Roche (RHHBY), have cancelled five studies on an experimental leukemia and lymphoma medicine after two patient deaths said an AbbVie spokesperson, adding that AbbVie and its partner, Roche Holding, suspended the dose-escalation portion of the studies to determine the amount of drug that is safest and most effective, reported Bloomberg Friday afternoon. Reference Link
News For ABBV;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 1, 2015
08:46 EDTRHHBYExelixis says FDA extends PDUFA action date for cobimetinib NDA
Subscribe for More Information
June 30, 2015
07:32 EDTABBVJuno pact leaves Celgene set for growth past Revlimid, says Deutsche Bank
Subscribe for More Information
05:30 EDTRHHBYGenentech reports ocrelizumab Phase III studies met primary, secondary endpoints
Subscribe for More Information
June 26, 2015
12:02 EDTABBVEMA adopts positive opinion on AbbVie's Humira for acne inversa
Subscribe for More Information
June 25, 2015
14:03 EDTRHHBYRoche initiated with a Buy at HSBC
Subscribe for More Information
June 24, 2015
09:07 EDTRHHBYCAR-T cancer drug researchers seen as M&A targets, Bloomberg says
Juno Therapeutics (JUNO), Kite Pharma (KITE) and Bluebird Bio (BLUE) are trading well above their IPO levels as takeovers predictions have spurred interest and share increases for the developers of CAR-T gene therapies, said Bloomberg's "Real M&A" column, quoting Dimo Dimov, a professor at the University of Bath’s School of Management, as having said that companies such as Pfizer (PFE), Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) are "closely watching" the firms. Cellectis (CLLS), which is working with Pfizer on its own approach to CAR-T therapy, has said it wants to bring its therapy to market and doesn’t anticipate a sale, the report noted. Reference Link
06:12 EDTABBVAbbVie announces new TURQUOISE-III study results
Subscribe for More Information
June 18, 2015
07:36 EDTABBVReceptos remains an attractive takeover candidate, says Leerink
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use